ARQT · Insider trading · 13F holders · Congress trades
Arcutis Biotherapeutics, Inc. (ARQT)
Who is buying and selling ARQT: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 19
- Insider buys, 90 days
- $0
- Insider sales, 90 days
- $2.3M
- Congress trades, 12 months
- 3
ARQT at a glance
- Between Aug 1, 2026 and Oct 29, 2026, 5 ARQT insiders filed 12 sales worth $2.3M on SEC Form 4, and no open-market purchases; 8 of the sales were pre-planned under Rule 10b5-1.
- 19 13F filers hold ARQT among their 50 largest positions, worth $1.0B combined. The biggest bets by portfolio weight are Pivotal bioVenture Partners Investment Advisor LLC (10.8%), Montanova Capital, LLC (6.9%) and Jones Hill Capital LP (6.1%). In their latest 13Fs, 1 manager opened a new position and 1 added to one.
- Members of Congress have disclosed 6 ARQT trades since 2022, 2 purchases and 1 sale in the past year; the latest was Gilbert Ray Cisneros, Jr. (D-CA), buying $1K–15K on May 29, 2026.
- ARQT last closed at $31.97 on Oct 29, 2026.
ARQT insider trading
Between Aug 1, 2026 and Oct 29, 2026, 5 ARQT insiders filed 12 sales worth $2.3M on SEC Form 4, and no open-market purchases; 8 of the sales were pre-planned under Rule 10b5-1.
| Filed | Insider | Role | Trade | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|---|
| Oct 19, 2026 | Welgus Howard G. | Director | Sale10b5-1 | 4,728 | $26.93 | $127K | SEC |
| Sep 18, 2026 | Matsuda Masaru | See Remarks | Sale10b5-1 | 3,674 | $25.00 | $92K | SEC |
| Sep 17, 2026 | Welgus Howard G. | Director | Sale10b5-1 | 4,730 | $24.18 | $114K | SEC |
| Sep 10, 2026 | Matsuda Masaru | See Remarks | Sale10b5-1 | 9,989 | $25.03 | $250K | SEC |
| Aug 28, 2026 | Curran Terrie | Director | Sale | 38,200 | $25.03 | $956K | SEC |
| Aug 24, 2026 | Curran Terrie | Director | Sale | 1,072 | $26.04 | $28K | SEC |
| Aug 21, 2026 | Burnett Patrick | See Remarks | Sale | 1,697 | $27.00 | $46K | SEC |
| Aug 19, 2026 | Welgus Howard G. | Director | Sale10b5-1 | 4,730 | $26.18 | $124K | SEC |
| Aug 13, 2026 | Burnett Patrick | See Remarks | Sale | 15,000 | $26.33 | $395K | SEC |
| Aug 5, 2026 | Watanabe Todd | See Remarks, Director | Sale10b5-1 | 4,375 | $26.12 | $114K | SEC |
| Aug 5, 2026 | Matsuda Masaru | See Remarks | Sale10b5-1 | 1,230 | $26.12 | $32K | SEC |
| Aug 5, 2026 | Burnett Patrick | See Remarks | Sale10b5-1 | 955 | $26.12 | $25K | SEC |
Who owns ARQT? Hedge funds and superinvestors
19 13F filers hold ARQT among their 50 largest positions, worth $1.0B combined. The biggest bets by portfolio weight are Pivotal bioVenture Partners Investment Advisor LLC (10.8%), Montanova Capital, LLC (6.9%) and Jones Hill Capital LP (6.1%). In their latest 13Fs, 1 manager opened a new position and 1 added to one.
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| Montanova Capital, LLCHedge fund | 6.9% | $326.1M | 12,437,000 | +0.9% shares | Q2 2026 |
| Frazier Life Sciences Management, L.P.Hedge fund | 5.6% | $258.9M | 9,874,511 | +0.0% shares | Q2 2026 |
| Rubric Capital Management LPHedge fund | 2.0% | $216.9M | 8,271,577 | +0.0% shares | Q2 2026 |
| Orbimed Advisors LLCHedge fund | 1.0% | $53.5M | 2,042,000 | — | Q2 2026 |
| Oberweis Asset Management Inc/Mutual fund manager | 0.7% | $36.0M | 1,372,941 | +0.5% shares | Q2 2026 |
| Pivotal bioVenture Partners Investment Advisor LLCVenture capital | 10.8% | $33.2M | 1,265,283 | -6.7% shares | Q2 2026 |
| Jones Hill Capital LPHedge fund | 6.1% | $28.6M | 1,089,701 | New | Q2 2026 |
| Simplify Asset Management Inc.Mutual fund manager | 0.4% | $22.9M | 865,862 | — | Q3 2026 |
| Fishman Jay A Ltd/miInvestment manager | 1.3% | $15.8M | 597,115 | +0.4% shares | Q3 2026 |
| Privium Fund Management B.V.Asset manager | 1.9% | $10.5M | 399,367 | +24.4% shares | Q2 2026 |
| Patient Square Capital LPHedge fund | 1.5% | $9.7M | 370,000 | -7.6% shares | Q2 2026 |
| MYDA Advisors LLCHedge fund | 1.5% | $6.3M | 240,000 | +0.0% shares | Q2 2026 |
| Pavaki Capital Management LLCHedge fund | 2.5% | $4.9M | 187,000 | +0.0% shares | Q3 2026 |
| Cormorant Asset Management, LPHedge fund | 0.2% | $4.6M | 175,000 | -61.1% shares | Q2 2026 |
| 1492 Capital Management LLCWealth manager | 0.9% | $3.0M | 116,211 | -1.6% shares | Q2 2026 |
| Tejara Capital LtdHedge fund | 1.2% | $3.0M | 113,084 | -32.0% shares | Q2 2026 |
| Ami Asset Management CorpWealth manager | 0.1% | $1.1M | 41,505 | — | Q3 2026 |
| PSP Research LLCInstitutional asset manager | 0.2% | $264K | 10,000 | -49.2% shares | Q3 2026 |
| Lion Point Capital, LPHedge fund | 0.7% | $138K | 5,250 | +0.0% shares | Q2 2026 |
Each manager counts with its latest 13F (Q3 2026: 5, Q2 2026: 14). Screen ARQT in the grand portfolio →
ARQT stock trades by members of Congress
Members of Congress have disclosed 6 ARQT trades since 2022, 2 purchases and 1 sale in the past year; the latest was Gilbert Ray Cisneros, Jr. (D-CA), buying $1K–15K on May 29, 2026.
| Filed | Member | Trade | Amount | Traded | Since |
|---|---|---|---|---|---|
| Jun 8, 2026 | Gilbert Ray Cisneros, Jr.D-CA · House | Buy | $1K–15K | May 29, 2026 | +50.3% |
| Apr 7, 2026 | Gilbert Ray Cisneros, Jr.D-CA · House | Buy | $1K–15K | Mar 3, 2026 | +36.6% |
| Jan 12, 2026 | Gilbert Ray Cisneros, Jr.D-CA · House | Sale | $1K–15K | Dec 11, 2025 | +9.4% |
| Oct 15, 2023 | Josh GottheimerD-NJ · House | Sale | $1K–15K | Sep 15, 2023 | +373.5% |
| May 19, 2023 | Josh GottheimerD-NJ · House | Buy | $1K–15K | Apr 17, 2023 | +130.7% |
| Jul 22, 2022 | Josh GottheimerD-NJ · House | Buy | $1K–15K | Jun 15, 2022 | +56.9% |
2 members have traded ARQT: Gilbert Ray Cisneros, Jr., Josh Gottheimer.
ARQT questions and answers
Are insiders buying ARQT stock?
Between Aug 1, 2026 and Oct 29, 2026, 5 ARQT insiders filed 12 sales worth $2.3M on SEC Form 4, and no open-market purchases; 8 of the sales were pre-planned under Rule 10b5-1.
Which hedge funds own ARQT?
19 13F filers hold ARQT among their 50 largest positions, worth $1.0B combined. The biggest bets by portfolio weight are Pivotal bioVenture Partners Investment Advisor LLC (10.8%), Montanova Capital, LLC (6.9%) and Jones Hill Capital LP (6.1%). In their latest 13Fs, 1 manager opened a new position and 1 added to one.
Has Congress traded ARQT?
Members of Congress have disclosed 6 ARQT trades since 2022, 2 purchases and 1 sale in the past year; the latest was Gilbert Ray Cisneros, Jr. (D-CA), buying $1K–15K on May 29, 2026.
Who is the largest holder of ARQT?
Among 13F filers, Montanova Capital, LLC reports the largest ARQT position, $326.1M (12,437,000 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is Pivotal bioVenture Partners Investment Advisor LLC's: 10.8% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.